MedTrace Logo

Ondansetron Oral Versus Orally Disintegrating Tablets (ODT)

NCT02174874 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 462

Last updated 2014-06-26

No results posted yet for this study

Summary

In children aged 3 months to 10 years who present to the Pediatric Emergency Department (PED) with recent, significant vomiting and moderate dehydration, is treatment with Ondansetron Orally Disintegrating Tablet (ODT) better tolerated than treatment with Ondansetron Oral Solution (OS)? Our hypothesis is that children who receive Ondansetron ODT will have 10% less vomiting within 15 minutes of administration than those receiving Ondansetron OS.

Conditions

  • Acute Gastroenteritis

Sponsors & Collaborators

  • Dr. Graham Thompson

    lead OTHER

Principal Investigators

  • Graham Thompson, Physician · Alberta Children's Hospital, Department of Pediatrics/Medicine, University of Calgary

  • David W Johnson, Physician · Alberta Children's Hospital, Department of Pediatrics/Medicine, University of Calgary

Eligibility

Min Age
3 Months
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-05-31
Completion
2014-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02174874 on ClinicalTrials.gov